Patents Issued in February 18, 2016
  • Publication number: 20160045455
    Abstract: The present invention is directed to method for the treatment of depression, for example, treatment resistant depression; wherein the treatment regimen is adjusted depending on the patient's genotype at SNP rs4306882.
    Type: Application
    Filed: August 12, 2015
    Publication date: February 18, 2016
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Wayne C. Drevets, Qingqin S. Li
  • Publication number: 20160045456
    Abstract: The present invention relates to phenylcyclopropylamine derivatives. In particular, pharmaceutical compositions comprising phenylcyclopropylamine derivatives are provided. The compounds of this invention can, inter alia, be used for the treatment and the prevention of cancer as well as neurodegenerative diseases or disorders.
    Type: Application
    Filed: February 20, 2015
    Publication date: February 18, 2016
    Inventors: Nathalie GUIBOURT, Alberto ORTEGA MUÑOZ, Julio CASTRO-PALOMINO LARIA
  • Publication number: 20160045457
    Abstract: The invention provides compositions including epinephrine fine particles, including epinephrine nanoparticles or nanocrystals and epinephrine microparticles or microcrystals, and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine fine particles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required.
    Type: Application
    Filed: March 24, 2014
    Publication date: February 18, 2016
    Inventors: Mutasem RAWAS-QALAJI, Ousama RACHID, Keith SIMONS, Estelle SIMONS
  • Publication number: 20160045458
    Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.
    Type: Application
    Filed: October 30, 2015
    Publication date: February 18, 2016
    Inventors: Klaus SCHIENE, Petra BLOMS-FUNKE, Thomas CHRISTOPH
  • Publication number: 20160045459
    Abstract: A combination comprising as components (a) the compound 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol, and (b) one or more non-steroidal anti-inflammatory drugs (NSAIDs); a pharmaceutical salt comprising said components; a compound derived from said components; a pharmaceutical formulation and a dosage form comprising said combination, salt, or compound; as well as a method of treating pain, e.g. chronic or acute pain, in a mammal characterized in that components (a) and (b) are administered simultaneously or sequentially to a mammal, wherein component (a) may be administered before or after component (b) and wherein components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.
    Type: Application
    Filed: October 30, 2015
    Publication date: February 18, 2016
    Inventors: Klaus SCHIENE, Petra BLOMS-FUNKE
  • Publication number: 20160045460
    Abstract: A water-based, alcohol-free, skin sanitizing and wound healing solution with a natural skin softener, where the nature of the biocidal enhancer used in the process of making the solution significantly increases efficacy while simultaneously enabling much more economical manufacturing, processing and transportation of the product. As the present solution is water-based, no further moisturizing additives are required, and those with sensitive skin, diabetes, allergies or religious beliefs are able to use the product without concern.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 18, 2016
    Inventors: David J. Weaver, Scott D. Buckley
  • Publication number: 20160045461
    Abstract: The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating mediated diseases.
    Type: Application
    Filed: October 23, 2015
    Publication date: February 18, 2016
    Inventors: Mark R. KELLEY, James H. WIKEL
  • Publication number: 20160045462
    Abstract: Provided herein are methods for treating pain such as acute or chronic pain or fever in subject without risking hepatotoxicity. The subject may be at risk of hepatotoxicity if administrated an acetaminophen monomer. The method includes administering a pharmaceutical composition containing an acetaminophen dimer compound, wherein the phenolic hydroxyl groups of two acetaminophen compounds are linked via an ethylene spacer.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Inventor: Nikhilish Nihala Singh
  • Publication number: 20160045463
    Abstract: The present invention comprises the use of metalloprotease inhibitors for the treatment of polycystic liver diseases (PLDs). The invention particularly describes the use of Marimastat as the preferred metalloprotease inhibitor for the treatment of PLDs. Treatment with Marimastat is able to inhibit liver cystogenesis by blocking metalloproteolytic hyperactivity of polycystic cholangiocytes.
    Type: Application
    Filed: November 27, 2013
    Publication date: February 18, 2016
    Applicant: UNIVERSIDAD DE SALAMANCA
    Inventors: Jesús Maria BAÑALES ASURMENDI, Luis BUJANDA PIEROLA, Elizabeth HIJONA MURUAMENDIARAZ, Patricia MÚÑOZ GARRIDO, Jesús PRIETO VALTUEÑA, Aura Daniela URRIBARRI, José Juan GARCÍA MARÍN, Maria Jesús PERUGORRIA MONTIEL, Elisa LOZANO ESTEBAN
  • Publication number: 20160045464
    Abstract: Methods are provided for preventing, inhibiting, or treating intimal hyperplasia in a patient who has undergone a coronary bypass procedure that include providing a solution comprising DCA added to water; and administering the solution orally to a patient to prevent, inhibit, or treat intimal hyperplasia.
    Type: Application
    Filed: April 20, 2015
    Publication date: February 18, 2016
    Inventors: Tobias Deuse, Sonja Schrepfer
  • Publication number: 20160045465
    Abstract: A pharmaceutical formulation of therapeutically effective amounts of acetaminophen, ibuprofen, and a sympathomimetic drug, such as pseudoephedrine (or its prodrug), or phenylephrine used in the treatment of cold and flu-like symptoms. Such symptoms may include fever, pain, nasal congestion, sinus congestion, runny nose, sore throat, myalgia, ear pressure and fullness, and headache. The formulation further includes various excipients used in the formulation process.
    Type: Application
    Filed: October 28, 2015
    Publication date: February 18, 2016
    Inventor: Mark Andrew Lomaga
  • Publication number: 20160045466
    Abstract: The field involves compositions useful for pain relief, including diclofenac solution and gel formulations, in particular methods of use thereof, articles of manufacture and kits that provide novel preclinical, clinical and other information to users.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Inventors: Jagat Singh, Joseph Zev Shainhouse, Bradley S. Galer, Robert Dominic King-Smith, Lisa Marie Grierson, Maria Burian, Jonathan Wilkin, Edward Kisak, John M. Newsam
  • Publication number: 20160045467
    Abstract: Nitro oleic acid and related metabolites are agonists of PPAR-?. Surprisingly, nitro oleic acid is a more potent agonist of PPAR-?, relative to nitro linoleic acid. Thus, nitro oleic acid and its metabolites, as well as their pharmaceutically acceptable salts and prodrug forms, are candidate therapeutics for the treatment of type-2 diabetes, which results from insulin resistance accompanying the improper functioning of PPAR-?.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Bruce A. Freeman, Francisco J. Schopfer
  • Publication number: 20160045468
    Abstract: Disclosed herein are compositions and methods for treating or preventing certain cancers in a subject. In certain embodiments such compositions and methods generally relate to the use of G-coupled protein receptor 40 (GPR40) agonists to inhibit the growth or induce apoptosis of certain cancer cells. The compositions and related methods disclosed herein may be used to treat subjects affected by cancers, such as melanoma, medullary thyroid carcinoma, malignant peripheral nerve sheath tumors and neuroblastoma, and to reduce the incidence of metastases in such affected subjects.
    Type: Application
    Filed: March 17, 2014
    Publication date: February 18, 2016
    Inventors: Mark Puder, Deepika Nehra, Brian Kalish
  • Publication number: 20160045469
    Abstract: Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI.
    Type: Application
    Filed: October 29, 2015
    Publication date: February 18, 2016
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuhiro YOKOYAMA, Hideki ORIGASA, Masunori MATSUZAKI, Yuji MATSUZAWA, Yasushi SAITO, Yuichi ISHIKAWA, Shinichi OIKAWA, Jun SASAKI, Hitoshi HISHIDA, Hiroshige ITAKURA, Toru KITA, Akira KITABATAKE, Noriaki NAKAYA, Toshiie SAKATA, Kazuyuki SHIMADA, Kunio SHIRATO
  • Publication number: 20160045470
    Abstract: The present application relates to the amorphous solid dispersion of treprostinil diethanolamine salt and the process for its preparation.
    Type: Application
    Filed: August 12, 2015
    Publication date: February 18, 2016
    Inventors: Peddireddy Subba Reddy, Jithin K. Jose
  • Publication number: 20160045471
    Abstract: A method for preparing an ingestible cannabis composition is provided. Also provided is the ingestible cannabis composition and a kit including the ingestible cannabis composition.
    Type: Application
    Filed: August 12, 2014
    Publication date: February 18, 2016
    Inventor: Kelly J. Stodola
  • Publication number: 20160045472
    Abstract: A composition includes a sufficient amount of urolithin B, or a derivative thereof, for increasing muscle cell size.
    Type: Application
    Filed: January 20, 2014
    Publication date: February 18, 2016
    Inventors: Fabian PRIEM, Julie RODRIGUEZ, Marc FRANCAUX, Fabienne FAUCHET
  • Publication number: 20160045473
    Abstract: A composition for a dietary supplement. The supplement may include: (a) an effective amount of amino acid and a biocompatible solvent, wherein the effective amounts of amino acid is between about 1 gram per day and about 20 grams per day; and (b) a food additive to aid in administration.
    Type: Application
    Filed: September 10, 2015
    Publication date: February 18, 2016
    Inventor: Rory Powell Blake
  • Publication number: 20160045474
    Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.
    Type: Application
    Filed: October 28, 2015
    Publication date: February 18, 2016
    Inventors: Rajesh Gandhi, Sreekanth MANIKONDA, Arun JANA, Sameer Shrinivas KUNTE
  • Publication number: 20160045475
    Abstract: Methods of treating, managing or preventing diseases ameliorated by inhibiting PDE4 such as psoriasis, ankylosing spondylitis, Behcet's disease, rheumatoid arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis are disclosed. Specific methods encompass the administration of apremilast in specific dosage titration schedule, alone or in combination with a second active agent.
    Type: Application
    Filed: August 13, 2015
    Publication date: February 18, 2016
    Inventor: Robert DAY
  • Publication number: 20160045476
    Abstract: The present technology provides compositions and methods for treating chronic kidney disease, end-stage renal disease, or diabetic nephropathy. The compositions comprise a nitrated lipid and an inhibitor of the renin-angiotensin-aldosterone system. The methods comprise administering a nitrated lipid in combination with an inhibitor of the renin-angiotensin-aldosterone system to a subject in need thereof, in an amount effective to treat diabetic nephropathy, chronic kidney disease, and/or end-stage renal disease. The use of a nitrated lipid with an inhibitor of the renin-angiotensin-aldosterone system exhibits a synergistic effect in treating chronic kidney disease and diabetic nephropathy.
    Type: Application
    Filed: October 23, 2015
    Publication date: February 18, 2016
    Inventor: Tianxin YANG
  • Publication number: 20160045477
    Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Inventors: Jan Wasley, Gary J. Rosenthal, Xicheng Sun, Sarah Strong, Jian Qiu
  • Publication number: 20160045478
    Abstract: The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.
    Type: Application
    Filed: October 27, 2015
    Publication date: February 18, 2016
    Inventors: Xicheng Sun, Jian Qiu
  • Publication number: 20160045479
    Abstract: A pharmaceutical composition containing, as the active ingredient, 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide, of which the solubility in an acidic pH region is different from that in a neutral pH region, with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance, is provided. The pharmaceutical composition for oral administration of the present invention contains 4-{[(1R,2s,3S,5s,7s)-5-hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide or a pharmaceutically acceptable salt thereof, and a hydrophilic lubricant, and is useful as a pharmaceutical composition for oral administration with rapid disintegration property and rapid drug dissolution property as well as the expectation of a good drug dosing compliance.
    Type: Application
    Filed: March 28, 2014
    Publication date: February 18, 2016
    Applicant: ASTELLAS PHARMA INC.
    Inventors: SEIJI TAKAE, HIROYUKI KOJIMA, ATSUSHI SAKURAI, TETSUYA TAMURA, HIROAKI TASAKI, ATSUSHI MURO
  • Publication number: 20160045480
    Abstract: Pharmaceutical compositions and methods for treating bacterial infections are disclosed.
    Type: Application
    Filed: January 13, 2014
    Publication date: February 18, 2016
    Inventors: Mahesh Vithalbhai PATEL, Sachin BHAGWAT, Prasad Keshav DESHPANDE
  • Publication number: 20160045481
    Abstract: The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.
    Type: Application
    Filed: October 27, 2015
    Publication date: February 18, 2016
    Inventors: Thorsten Degenhardt, Robert Schotzinger, J. Wesley Fox
  • Publication number: 20160045482
    Abstract: The disclosure relates to compounds of formula (I) for use in the treatment or prophylaxis of rhinovirus infection, methods of treating or preventing rhinovirus infection employing said compounds or pharmaceutical composition comprising the same. The disclosure also relates to compounds of formula (I) for use in the treatment or prophylaxis of exacerbation of respiratory disorders (such as asthma, COPD, bronchitis and/or cystic fibrosis) by rhinovirus infection.
    Type: Application
    Filed: October 27, 2015
    Publication date: February 18, 2016
    Applicant: Respivert Limited
    Inventors: Catherine Elisabeth Charron, Kazuhiro Ito, William Garth Rapeport
  • Publication number: 20160045483
    Abstract: Provided herein are solid forms comprising (a) 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (Lenalidomide) and (b) a coformer. Pharmaceutical compositions comprising the solid forms and methods for treating, preventing and managing various disorders are also disclosed.
    Type: Application
    Filed: March 25, 2014
    Publication date: February 18, 2016
    Applicant: CELGENE CORPORATION
    Inventors: G. Patrick STAHLY, David JONAITIS, Ho-Wah HUI, Kevin J. KLOPFER
  • Publication number: 20160045484
    Abstract: Methods and compositions for treating, preventing or managing central nervous system cancers are disclosed. The methods encompass the administration of 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione, also known as Pomalidomide. Furthermore, provided herein are methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.
    Type: Application
    Filed: April 1, 2014
    Publication date: February 18, 2016
    Inventor: Han W. TUN
  • Publication number: 20160045485
    Abstract: The present invention relates to the new use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3?) inhibitors and to their use in the treatment of GSK-3?-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.
    Type: Application
    Filed: August 13, 2015
    Publication date: February 18, 2016
    Applicant: Aziende Chimiche Riunite Angelini Francesco A.C.R. A.F. S.P.A.
    Inventors: Maria Alessandra ALISI, Nicola Cazzolla, Barbara Garofalo, Guido Furlotti, Gabriele Magaro', Rosella Ombrato, Francesca Mancini
  • Publication number: 20160045486
    Abstract: Trans-hexahydrobenzoaphenanthridines of the formula (I) wherein X, Y, R1, R2, R3, R4, R5, R6, and R7 are as defined herein, are disclosed. Pharmaceutical formulations including such compounds, and methods of using such compounds for treating a patient suffering from dopamine-related dysfunction of the central or peripheral nervous system are also disclosed.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Inventor: Richard B. Mailman
  • Publication number: 20160045487
    Abstract: The invention features XIB4035 for the treatment of large fiber neuropathy, and combinations of XIB4035 and GDNF for the treatment of both large and small fiber neuropathies.
    Type: Application
    Filed: March 26, 2014
    Publication date: February 18, 2016
    Inventor: Gabriel Corfas
  • Publication number: 20160045488
    Abstract: The present application relates to cycloalkylpyridin-2-amines derivates of formula (I) or stereoisomers thereof or pharmaceutically acceptable salts thereof. The present application also relates to the process for the preparation of compounds of formula (I). The present application further describes the compounds of formula (I) as cholesteryl ester-transfer protein (CETP) inhibitors. The present application further relates to pharmaceutical compositions comprising compounds of formula (I) or stereoisomers thereof or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: October 20, 2015
    Publication date: February 18, 2016
    Inventors: Anima BORUAH, Shanavas ALIKUNJU
  • Publication number: 20160045489
    Abstract: The present invention relates to novel N-(imidazolidin-2-ylidene)quinoline derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Application
    Filed: October 28, 2015
    Publication date: February 18, 2016
    Inventors: Santosh C. Sinha, Liming Wang, Ken Chow, Mohammed I. Dibas, Michael E. Garst
  • Publication number: 20160045490
    Abstract: The use of chemotherapeutic agents for the preparation of a medicament for the topical and/or local treatment of diseases caused by bacteria and/or for prophylaxis in humans or animals.
    Type: Application
    Filed: October 5, 2015
    Publication date: February 18, 2016
    Inventors: Hans-Herrmann SCHULZ, Guenther SCHLIMBACH
  • Publication number: 20160045491
    Abstract: During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week.
    Type: Application
    Filed: October 28, 2015
    Publication date: February 18, 2016
    Inventor: Richard A. Smith
  • Publication number: 20160045492
    Abstract: During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to swallow and/or speak, among victims of stroke, head injury, or ALS. Improved higher mental functioning has been exemplified in better job performance, increased ability to analyze and solve problems, and increased ability to have successful and satisfying interactions with other people. These types of effects can be seen in a relatively brief time period, such as within several days to a week.
    Type: Application
    Filed: October 28, 2015
    Publication date: February 18, 2016
    Inventor: Richard A. Smith
  • Publication number: 20160045493
    Abstract: The invention provides a method of treating a joint condition. The method comprises administering a multi-dose regimen of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a method of treating osteoarthritis with multiple doses of a low-molecular weight fraction of human serum albumin.
    Type: Application
    Filed: August 18, 2015
    Publication date: February 18, 2016
    Inventor: David Bar-Or
  • Publication number: 20160045494
    Abstract: A method for determining the risk of cardiovascular disease in a subject having a chronic viral infection includes determining a level of ectonucleotide pyrophosphatase/phosphodiesterase-2 (ENPP2) in the subject and comparing the determined level of ENPP2 to a control level, wherein an increased level of ENPP2 is indicative of the subject having an increased risk of cardiovascular disease associated with the chronic viral infection.
    Type: Application
    Filed: August 15, 2014
    Publication date: February 18, 2016
    Inventor: Mark R. Chance
  • Publication number: 20160045495
    Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.
    Type: Application
    Filed: August 17, 2015
    Publication date: February 18, 2016
    Applicant: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Philip CRESSWELL, Sara Montminy Paquette, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Ryan Turncliff, Michael Palmieri, Tarek Zeidan, Ethan P. Cash, Marjie L. Hard
  • Publication number: 20160045496
    Abstract: The invention relates to the use of (R)-S-cyclopropyl-S-(4-{[4-{[(1R, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide and/or (S)-S-cyclopropyl-S-(4-{[4-{[(1R, 2R)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulphoximide for treating specific tumours.
    Type: Application
    Filed: February 28, 2014
    Publication date: February 18, 2016
    Inventors: Gerhard SIEMEISTER, Vincent RIBRAG, Valérie CAMARA-CLAYETTE
  • Publication number: 20160045497
    Abstract: The present invention relates to a pharmaceutical composition including valsartan and rosuvastatin calcium as active ingredients, and a manufacturing method therefor. The pharmaceutical composition including valsartan and rosuvastatin calcium according to the present invention can alleviate side effects of the existing single preparations and simultaneously improve compliance of patients having a cardiovascular disease, a hyperlipidemic disease and a complex disease thereof, and increases treatment and prevention effects, and in particular, obtains synergistic effects in treating hyperlipidemia, and enhances the dissolution rate of valsartan and rosuvastatin calcium and treatment effects by granulating valsartan and mixing rosuvastatin calcium.
    Type: Application
    Filed: March 11, 2014
    Publication date: February 18, 2016
    Applicant: LG LIFE SCIENCES LTD.
    Inventors: Jeong Uk SONG, Geun Tae KIM, Sun Il KIM, Ki Kon LEE
  • Publication number: 20160045498
    Abstract: The present invention relates to a method of treating or preventing a disease characterized by excessive Wnt signalling, such as colorectal cancer, by administering a compound which inhibits the activity of one or more of JAK2, JAK1 or TYK2.
    Type: Application
    Filed: April 4, 2014
    Publication date: February 18, 2016
    Inventors: Matthias Robert Walter Ernst, Toby James Phesse, Michael Buchert, Emma Charlotte Stuart
  • Publication number: 20160045499
    Abstract: Methods for treating androgen receptor related diseases and suppressing androgen receptor related function by administering an effective amount of minoxidil are provided. Methods for treating or prophylactically treating acne by administering an effective amount of minoxidil are also provided. An anti-acne medication is optionally administered to treat or prophylactically treat acne.
    Type: Application
    Filed: April 30, 2014
    Publication date: February 18, 2016
    Inventor: CHENG-LUNG Hsu
  • Publication number: 20160045500
    Abstract: The invention concerns a spiro-amino compound of Formula (I), wherein A is selected from a 5- or 6-membered aromatic ring and a 5- or 6-membered heteroaromatic ring containing 1 to 3 nitrogen atom; X is a substituent selected from the group consisting of (C1-C3)alkyl and halogen, Y is a substituent selected from the group consisting of halogen and trifluoromethyl or a pharmaceutically acceptable salt thereof for use in the treatment of pathologies which require an antagonist of the NK1 receptor.
    Type: Application
    Filed: October 26, 2015
    Publication date: February 18, 2016
    Inventors: Luigi Piero STASI, Lucio ROVATI
  • Publication number: 20160045501
    Abstract: The invention relates to a method of treating proliferative diseases mediated by the tyrosine kinase receptor KIT, in particular GIST, in a human patient population.
    Type: Application
    Filed: October 27, 2015
    Publication date: February 18, 2016
    Applicant: Novartis AG
    Inventors: Yanfeng Wang, Elisabeth Wehrle
  • Publication number: 20160045502
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to mustard-based alkylating agents such as uracil mustard and analogs, derivatives, or prodrugs thereof, including 6-methyluracil mustard and 6-ethyluracil mustard.
    Type: Application
    Filed: April 8, 2014
    Publication date: February 18, 2016
    Inventor: Dennis M. BROWN
  • Publication number: 20160045503
    Abstract: Oral pharmaceutical formulations comprising reversible covalent compounds having a Michael acceptor moiety, a process of their production and use of these formulations for the treatment of diseases treatable by such compounds such as cancer and autoimmune diseases.
    Type: Application
    Filed: June 11, 2013
    Publication date: February 18, 2016
    Inventors: David Michael Goldstein, Bret BERNER
  • Publication number: 20160045504
    Abstract: The invention relates generally to effective treatment leukemia. In particular, the present invention provides compositions and methods to inhibit the interaction of menin with MLL and MLL-fusion oncoproteins, and well as systems and methods to screen for such compositions.
    Type: Application
    Filed: March 23, 2015
    Publication date: February 18, 2016
    Inventors: Jolanta Grembecka, Tomasz Cierpicki, Jay Hess